Healthspan Post

NMN clinical trials

NMN clinical trials: tested in people? Blood NAD+ rose.

NMN has been tested in people: NMN clinical trials found higher blood NAD+, with walking and sleep findings specific to the trials.

Reader-supported: this page has affiliate links to Renue By Science. If you buy through them we earn a commission, which funds our research. We choose what to cover independently. How we’re funded

By the Healthspan Post team

· 3 min read

Evidence: 5 papers, 3 human studies, 2 reviews.

  • A 5 human RCT, meta-analysis or systematic review
Research and article information

How we made this. Checked against every study we cite. It is not medical advice.

Updated:

How we check · Methodology · Is NMN legal in US supplements? · Corrections · How we’re funded

The evidence

5

studies behind this article

3 human studies · 2 reviews

  • 5 study design grade A

NMN clinical trials have measured higher blood NAD+ in people. In a randomized, placebo-controlled trial of 60 older adults, 250 mg a day for 12 weeks raised blood NAD+ versus placebo, a secondary outcome (Morifuji et al., 2024, Geroscience: PubMed).

Bottom line

The trials provide evidence of higher blood NAD+, specific walking and sleep findings, and short-term tolerability in the populations studied. Those findings do not establish slower human aging or an equivalent result for a commercial jar (Morifuji et al., 2024, Geroscience: PubMed; Gallagher and Emmanuel, 2026, Ageing Res Rev: PubMed).

What did NMN clinical trials measure?

In the 60-person trial, blood NAD+ and its metabolites were higher after 12 weeks. These were secondary findings, alongside a shorter 4-meter walking time and better sleep-quality scores than placebo (Morifuji et al., 2024, Geroscience: PubMed).

A separate randomized, double-blind, placebo-controlled trial included 80 healthy middle-aged adults. Oral NMN at 300, 600 or 900 mg once daily for 60 days increased blood NAD+ and six-minute walking distance versus placebo. Blood NAD+ concentrations were highest in the 600 and 900 mg groups (Yi et al., 2023, Geroscience: PubMed). These were measured endpoints, rather than a promise of how a buyer will feel.

The studies ran from 4 weeks to 12 weeks

  • Fukamizu 2022 1250 mg once daily

    Measured: Safety assessments in 31 healthy adults aged 20–65; exposure lasted up to 4 weeks

  • Yi 2023 300, 600 or 900 mg once daily

    Measured: Blood NAD+ and six-minute walking distance in a trial of 80 healthy middle-aged adults

  • Morifuji 2024 250 mg a day

    Measured: Secondary outcomes in 60 older adults: blood NAD+ and metabolites, 4-meter walking time and sleep quality

The dose each human trial used and how long it lasted, as its abstract reports. Longer bars mean longer trials.

Source: Healthspan Post summary of the cited trials (PubMed).

What does the safety evidence establish?

A randomized, double-blind, placebo-controlled trial of 31 healthy adults aged 20–65 evaluated 1,250 mg once daily for up to four weeks. Researchers judged it safe and well tolerated within that setting; no severe adverse events were observed (Fukamizu et al., 2022, Sci Rep: PubMed).

A systematic review and meta-analysis included 15 trials, with 10 contributing to safety analyses. Doses ranged from 250 to 2,000 mg a day and durations from 14 days to 24 weeks.

Its conclusion was favorable short-term tolerability for oral NMN or NMN-related preparations, rather than a guarantee for every person or duration (Yang et al., 2026, Nutrients: PubMed).

Does “33 human studies” mean 33 NMN trials?

The review counted 33 human intervention studies, including 28 randomized studies, alongside 80 rodent studies. It covered several NAD-related compounds and administration routes.

Its human findings described oral NR and NMN as consistently raising NAD-related metabolites and generally well tolerated over weeks to months. The count is not 33 trials of oral NMN alone (Gallagher and Emmanuel, 2026, Ageing Res Rev: PubMed).

Human trial findings: NAD+, walking and sleep measures

  • Blood NAD+ versus placebo, 12 weeks; secondary outcome in 60 older adultsImproved, size not reported · Morifuji 2024
  • Six-minute walking distance versus placebo, 60 days; 80 healthy middle-aged adultsImproved, size not reported · Yi 2023
  • Sleep-quality scores versus placebo, 12 weeks; secondary outcome in 60 older adultsImproved, size not reported · Morifuji 2024

What the trials found for each outcome, as each study's abstract reports it. A tick marks an improvement the study reported; its size was not reported.

Source: Healthspan Post summary of the cited studies (PubMed).

Does the scoop match a tested dose?

NMN Pure Powder lists 500 mg per 0.5 g scoop, no other ingredients and 200 servings per 100 g jar. That amount falls between the 300 and 600 mg daily doses in the 80-person trial; 500 mg was not one of that trial’s doses (Yi et al., 2023, Geroscience: PubMed).

Label amounts describe contents, rather than absorbed amounts. The supplied abstracts do not establish this commercial powder’s performance under the tongue.

For related reading, see our article on oral NMN and the gut.

The product we read

NMN Pure Powder offers 500 mg of NMN per labeled scoop and 200 labeled servings per jar. Renue says it supports NAD+ levels that help power your cells. Code HEALTHSPAN: 10% off. See NMN Pure Powder at Renue By Science

What we checked

Lab result vs label
100.1% of the NMN on the label. Lot 072827576, Summit Nutritional Laboratories
Cost per 500 mg
$0.27 Median across Renue's NMN range: $0.92
Where it sits in Renue's NMN range, cost per 500 mg
This product · $0.27NMN Pure Powder: $0.27 per 500 mgNMN SLC Enteric Capsules 200: $0.59 per 500 mgNMNs Fast Dissolve Tabs: $0.92 per 500 mgNMN Liposomal Capsules: $1.44 per 500 mgNMN Resveratrol Gel: $1.78 per 500 mgNMN Pure Powder: $0.27 per 500 mgLowest $0.27Highest $1.78

This product Same-molecule products · USD per 500 mg · Prices checked November 12, 2026

Products and prices
  • NMN Pure Powder: $0.27
  • NMN SLC Enteric Capsules 200: $0.59
  • NMNs Fast Dissolve Tabs: $0.92
  • NMN Liposomal Capsules: $1.44
  • NMN Resveratrol Gel: $1.78
Human studies in this article
3 3 randomized trials (study design grade A)

COA reviewed October 10, 2026: we read the certificates of analysis Renue publishes; we don't run lab tests ourselves. Every report we checked · Price index

Questions readers ask

Has NMN been tested in people?

Yes. A randomized, placebo-controlled trial of 80 healthy middle-aged adults found higher blood NAD+ with 300, 600 or 900 mg once daily for 60 days. Source

Did the older-adult trial measure more than blood NAD+?

Yes. In a randomized trial of 60 older adults taking NMN or placebo for 12 weeks, 250 mg daily produced a shorter 4-meter walking time and better sleep-quality scores than placebo. These were secondary outcomes. Source

What does the higher-dose safety trial establish?

Researchers judged 1,250 mg once daily safe and well tolerated in a randomized trial of 31 healthy adults aged 20–65 for up to four weeks; no severe adverse events were observed. Source

Were all 33 human studies trials of oral NMN?

No. The review covered several NAD-related compounds and administration routes. Its 33 human intervention studies included 28 randomized studies; it also included 80 rodent studies. Source

Does the scoop match a tested dose?

NMN Pure Powder lists 500 mg per scoop. The article compares that label amount with the 300 and 600 mg daily trial doses on either side of it. This is an ingredient-quantity comparison, not evidence of equivalent absorption or a result for this jar.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Support our research

References

View all 5 cited studies
  1. Morifuji M, Higashi S, Ebihara S, et al. (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. Geroscience. PubMed 38789831
  2. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. PubMed 36482258
  3. Fukamizu Y, Uchida Y, Shigekawa A, et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. PubMed 36002548
  4. Yang W, Huang J, Tang Z, et al. (2026). Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. PubMed 42514320
  5. Gallagher C, Emmanuel OO (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. PubMed 41655607